Printer Friendly

NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT

 SEATTLE, Wash., April 16 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced that Jeffrey J. Miller, Ph.D., J.D., has been promoted to senior vice president, business development and legal affairs. Dr. Miller received his Ph.D. in biophysics from the University of California and his J.D. degree from Loyola University, Los Angeles. Prior to joining NeoRx he was a partner in the nationally renowned patent law firm, Seed & Berry, and served a special assistant attorney general to the State of Washington. In that capacity, he represented the University of Washington in the case Ex Parte Allen, in an appeal establishing the principle that animals are patentable subject matter in the United States.
 Dr. Miller joined NeoRx as its vice president and general counsel in 1987. He later added the functions of vice president of business development and corporate secretary to his roles. Most recently, he established and manages NeoRx's strategic alliance with Boehringer Ingelheim that includes responsibility for registration of NeoRx's first product. He also serves on the board of directors of the Biotechnology Institute in Washington, D.C.
 "Dr. Miller's addition to NeoRx's management in 1987 began a period of timely and efficient patent filing and approvals of NeoRx's rich scientific discovery pipeline that had been languishing," said Paul Abrams, NeoRx's president and CEO. "Since that time his role has continually expanded, so that he played a major role in engineering NeoRx's turnaround, while maintaining the quality and output of the company's patent department. He is now responsible for nurturing our current strategic alliance with Boehringer Ingelheim and for establishing additional partnerships that will leverage the potent product pipeline that we have developed. We are delighted that he has accepted this new range of responsibilities, and look forward to continued success."
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA its OncoTrac(R) Small Cell Lung Cancer Imaging Product and has completed a phase III trial for a non-small cell lung cancer imaging agent. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 4/16/93
 /CONTACT: Robert M. Littauer, senior vice president and chief financial officer of NeoRx, 206-286-2519; or Bonnie K. Sterling of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU: PER

TS-LR -- NY018 -- 6647 04/16/93 09:57 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 16, 1993
Words:414
Previous Article:NEORX PROMOTES ROBERT LITTAUER TO SENIOR VICE PRESIDENT
Next Article:UNION TEXAS PETROLEUM DECLARES COMMON STOCK DIVIDEND
Topics:


Related Articles
NEORX SIGNS SECOND COLLABORATIVE RESEARCH AGREEMENT WITH GENENTECH
NEORX DECLARES DIVIDEND
NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT
NEORX APPOINTS ROBERT SCHROFF AS VICE PRESIDENT & GENERAL MANGER, CARDIOVASCULAR PRODUCTS
NEORX PROMOTES ROBERT LITTAUER TO SENIOR VICE PRESIDENT
NEORX REPORTS SECOND QUARTER 1993 RESULTS
NEORX REPORTS 1994 FIRST QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters